Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 10, Pages 2870
Publisher
MDPI AG
Online
2020-10-06
DOI
10.3390/cancers12102870
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?
- (2020) Vildan B. Cetintas et al. Journal of Translational Medicine
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- FOXD3 Regulates VISTA Expression in Melanoma
- (2020) Sheera R. Rosenbaum et al. Cell Reports
- Melanoma-Derived Exosomal miR-125b-5p Educates Tumor Associated Macrophages (TAMs) by Targeting Lysosomal Acid Lipase A (LIPA)
- (2020) Dennis Gerloff et al. Cancers
- Oncolytic adenovirus ORCA‐010 increases the type 1 T cell stimulatory capacity of melanoma‐conditioned dendritic cells
- (2020) M. López González et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism
- (2020) Ching-Liang Chu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- TRAF6 Activates Fibroblasts to Cancer-Associated Fibroblasts through FGF19 in Tumor Microenvironment to Benefit the Malignant Phenotype of Melanoma Cells
- (2020) Yeye Guo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells
- (2020) Yifan Zhou et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells
- (2019) Zhaoduan Liang et al. CANCER LETTERS
- Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
- (2019) Claudia TROJANIELLO et al. Expert Review of Clinical Pharmacology
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Ulrich Keilholz et al. Journal for ImmunoTherapy of Cancer
- PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
- (2019) Chiara Bazzichetto et al. Cancers
- Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
- (2019) M. A. F. Yahaya et al. Journal of Immunology Research
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
- (2019) Ziqian Li et al. INTERNATIONAL JOURNAL OF CANCER
- KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
- (2019) Da Meng et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrins, CAFs and Mechanical Forces in the Progression of Cancer
- (2019) Imjoo Jang et al. Cancers
- Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab
- (2019) Omid Hamid et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumor-mediated immune suppression
- (2019) Marta López González et al. OncoImmunology
- RAF kinases are stabilized and required for dendritic cell differentiation and function
- (2019) Kristina Riegel et al. CELL DEATH AND DIFFERENTIATION
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
- (2019) Andrea Vannini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
- (2019) Saei et al. Cancers
- B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
- (2019) Johannes Griss et al. Nature Communications
- New avenues for melanoma immunotherapy: Natural Killer cells?
- (2019) Costanza Maria Cristiani et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages
- (2018) Yufei Zhang et al. BIOMACROMOLECULES
- Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
- (2018) Ana Costa et al. CANCER CELL
- Non-conventional Inhibitory CD4 + Foxp3 − PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- (2018) Roberta Zappasodi et al. CANCER CELL
- VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
- (2018) Lawrence F. Kuklinski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cutaneous melanoma: From pathogenesis to therapy (Review)
- (2018) Giulia Leonardi et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
- (2018) Anais Del Curatolo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
- (2018) Ruixia Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma
- (2018) James Hutchenreuther et al. MATRIX BIOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
- (2018) Elisa Peranzoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy of melanoma
- (2018) Iwona Lugowska et al. Wspolczesna Onkologia-Contemporary Oncology
- Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
- (2018) Mélanie Saint-Jean et al. Journal of Immunology Research
- Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
- (2018) Feifei Liu et al. Acta Pharmaceutica Sinica B
- Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1- profile in a TLR4-dependent manner
- (2018) Carlos W Wanderley et al. CANCER RESEARCH
- Role of mTOR Signaling in Tumor Microenvironment: An Overview
- (2018) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- MEK inhibitors for the treatment of NRAS mutant melanoma
- (2018) Saro Sarkisian et al. Drug Design Development and Therapy
- NFAT1 enhances the effects of tumor-associated macrophages on promoting malignant melanoma growth and metastasis
- (2018) Hao Liu et al. BIOSCIENCE REPORTS
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
- (2018) Hanjie Li et al. CELL
- CAR-T cell therapy in melanoma: A future success story?
- (2018) Bianca Simon et al. EXPERIMENTAL DERMATOLOGY
- Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
- (2018) Veronica Huber et al. JOURNAL OF CLINICAL INVESTIGATION
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- 3D Coculture Models Underline Metastatic Melanoma Cell Sensitivity to Vemurafenib
- (2018) Delphine Morales et al. TISSUE ENGINEERING PART A
- Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
- (2018) Elena Gianchecchi et al. Frontiers in Immunology
- The Broad Spectrum of Human Natural Killer Cell Diversity
- (2017) Aharon G. Freud et al. IMMUNITY
- Tricking the balance: NK cells in anti-cancer immunity
- (2017) Jens Pahl et al. IMMUNOBIOLOGY
- Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin
- (2017) Begum Erdogan et al. JOURNAL OF CELL BIOLOGY
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
- (2017) Udupi A. Ramagopal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
- (2017) Rajasekharan Somasundaram et al. Nature Communications
- Immune system and melanoma biology: a balance between immunosurveillance and immune escape
- (2017) Anna Passarelli et al. Oncotarget
- Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion
- (2017) Linda Ziani et al. Oncotarget
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
- (2017) Aibin Zhang et al. Cancer Medicine
- Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
- (2017) Sheila López-Cobo et al. OncoImmunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness
- (2016) Njainday Pulo Jobe et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
- (2016) Amanpreet Kaur et al. NATURE
- Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
- (2016) YAO YUAN et al. ONCOLOGY REPORTS
- Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation
- (2016) Silvana Sandri et al. PHARMACOLOGICAL RESEARCH
- Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
- (2016) Mark J. Selby et al. PLoS One
- Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
- (2016) Baihao Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted deactivation of cancer-associated fibroblasts by β-catenin ablation suppresses melanoma growth
- (2016) Linli Zhou et al. TUMOR BIOLOGY
- Cancer-associated fibroblasts in hepatocellular carcinoma
- (2016) Norio Kubo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
- (2015) Eishu Hirata et al. CANCER CELL
- Targeted therapy in cancer
- (2015) Apostolia-Maria Tsimberidou CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
- (2015) Hideyuki Takahashi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
- (2015) T. Wang et al. CLINICAL CANCER RESEARCH
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- (2015) Zeynep Eroglu et al. EUROPEAN JOURNAL OF CANCER
- Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma
- (2015) Claudia Capparelli et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
- (2015) Inna V. Fedorenko et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
- (2015) I V Fedorenko et al. ONCOGENE
- FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor
- (2015) Connull Leslie et al. PATHOLOGY
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
- (2015) Kazuyoshi Shiga et al. Cancers
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
- (2015) William H. Chappell et al. Oncotarget
- PD-1 and PD-L1 antibodies for melanoma
- (2015) Katy K Tsai et al. Human Vaccines & Immunotherapeutics
- Myeloid-derived suppressor cell heterogeneity in human cancers
- (2014) Samantha Solito et al. Annals of the New York Academy of Sciences
- Melanoma immunotherapy
- (2014) Martina Sanlorenzo et al. CANCER BIOLOGY & THERAPY
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- Myeloid-derived suppressor cells in malignant melanoma
- (2014) Viktor Umansky et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin
- (2014) Manoela Tiago et al. TISSUE ENGINEERING PART A
- The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF
- (2014) M. P. Smith et al. Cancer Discovery
- Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
- (2013) Simone M. Goldinger et al. EJC SUPPLEMENTS
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- PTEN functions as a melanoma tumor suppressor by promoting host immune response
- (2013) Y Dong et al. ONCOGENE
- Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14+ Cells at the Cross-Roads of Immune Activation and Suppression
- (2013) Rieneke van de Ven et al. Frontiers in Immunology
- CD4+T Cells: Differentiation and Functions
- (2012) Rishi Vishal Luckheeram et al. Clinical & Developmental Immunology
- Melanoma: from mutations to medicine
- (2012) H. Tsao et al. GENES & DEVELOPMENT
- Microenvironment and tumor progression of melanoma: New therapeutic prospectives
- (2012) Gerardo Botti et al. Journal of Immunotoxicology
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Melanoma-infiltrating dendritic cells
- (2012) Jared S. Klarquist et al. OncoImmunology
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance
- (2011) Edward H. Flach et al. MOLECULAR PHARMACEUTICS
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
- (2010) Paolo A Ascierto et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
- (2010) Despina Handolias et al. Pigment Cell & Melanoma Research
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
- (2010) Antoni Ribas SEMINARS IN ONCOLOGY
- HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future
- (2009) Giulio Tosti et al. Expert Review of Vaccines
- KIT Gene Mutations and Copy Number in Melanoma Subtypes
- (2008) C. Beadling et al. CLINICAL CANCER RESEARCH
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started